

CONGRESS HIGHLIGHTS

ASCO 2023: Targeted Therapy for Early-Stage NSCLC

Roy Herbst¹

¹ Yale Cancer Center, New Haven, Connecticut, USA

Keywords: osimertinib, NSCLC, EGFR-mutated, Viewpoints, ASCO 2023

<https://doi.org/10.36000/hbT.OH.2023.16.113>

healthbook TIMES Oncology Hematology

Vol. 16, Issue 2, 2023

ADAURA: Final OS analysis reinforced adjuvant osimertinib as the standard of care for patients with resected *EGFR*-mutated stage IB-IIIa NSCLC

The final data from a randomized, double-blind, phase III ADAURA study presented at the 2023 ASCO Annual Meeting showed that osimertinib significantly and clinically meaningfully improved overall survival (OS) versus placebo in patients with resected *EGFR*-mutated stage IB–IIIa non-small cell lung cancer (NSCLC).^{1,2} More specifically, at a median follow-up of around 61 months, osimertinib was associated with a 51% reduction in the risk of death (HR: 0.49 [95.03% CI: 0.33–0.73]; $p=0.0004$) in the subset of patients with stage II/IIIa disease. The 60-month OS rates were 85% in the osimertinib and 73% in the placebo arm. These results follow the primary analysis in 2020 that demonstrated significantly extended disease-free survival (DFS) with osimertinib versus placebo (HR: 0.17 [99.06% CI: 0.11–0.26]; $p<0.001$).³ Based on these data, osimertinib is positioned as the standard of care therapy for metastatic disease that prolongs survival in this patient population and may even offer a cure for some patients. Indeed, targeted therapy for early-stage disease is a new paradigm for lung cancer.

Conflict of interest

The author reports consulting roles with AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Cybrexa Therapeutics, eFFECTOR Therapeutics, Eli Lilly, EMD Serono, Genentech/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Sanofi, Seattle Genetics, Shire, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics; advisory board roles with AstraZeneca, Bolt Biotherapeutics, Cybrexa Therapeutics, EMD Serono, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Neon

Therapeutics, Novartis and STCube Pharmaceuticals; research support from AstraZeneca, Eli Lilly, Genentech/Roche and Merck; and non-executive board membership for Junshi Pharmaceuticals and Immunocore.

Funding

The author has declared that no financial support was received from any organization for the submitted work.

Author Contributions

The author created and approved the final manuscript.



This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-NC-SA-4.0). View this license's legal deed at <https://creativecommons.org/licenses/by-nc-sa/4.0> and legal code at <https://creativecommons.org/licenses/by-nc-sa/4.0/legalcode> for more information.

REFERENCES

1. Herbst RS, Tsuboi M, John T, et al. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). Presented at: 2023 ASCO Annual Meeting; 2–6 June 2023. Chicago, IL, USA. Oral presentation LBA3.
2. Herbst RS, Wu YL, John T, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. *J Clin Oncol*. 2023;41(10):1830-1840. [doi:10.1200/jco.22.02186](https://doi.org/10.1200/jco.22.02186)
3. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected *EGFR*-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med*. 2020;383(18):1711-1723. [doi:10.1056/nejmoa2027071](https://doi.org/10.1056/nejmoa2027071)